This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AMBI Ambit Biosciences (AMBI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisNews and Trends About Ambit Biosciences Stock (NASDAQ:AMBI) Get Ambit Biosciences alerts:Sign Up Key Stats Today's Range$0.54▼$0.5450-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume5,081 shsMarket Capitalization$29.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company's lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company's second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company's third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase. Read More Receive AMBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ambit Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMBI Stock News HeadlinesAmbica Agarbathies Extends Trading Window Closure Ahead of Q4 ResultsMarch 30, 2026 | tipranks.com$TXG stock is down 10% today. Here's what we see in our data.March 16, 2026 | quiverquant.comQYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe calls it The 10-Minute Guide to Start Trading Options Today, built to help you open your first options trade with less capital than buying shares outright. | True Market Insiders (Ad)$IPGP stock is down 10% today. Here's what we see in our data.March 12, 2026 | quiverquant.comQAmbi Robotics Introduces AmbiVision, Utilizing AI Skill Suite for Image-Based Item Intelligence and Cognitive OCR for Distribution CentersMarch 11, 2026 | tmcnet.comAMBIQ MICRO ($AMBQ) Releases Q4 2025 EarningsMarch 5, 2026 | quiverquant.comQAMBITION DX HOLDINGS Outlines Q2 FY2026 Results and Real Estate DX StrategyMarch 5, 2026 | tipranks.comCytek Biosciences Inc. (CTKB) Stock Falls on Q4 2025 EarningsFebruary 26, 2026 | quiverquant.comQSee More Headlines AMBI Stock Analysis - Frequently Asked Questions How were Ambit Biosciences' earnings last quarter? Ambit Biosciences Corporation (NASDAQ:AMBI) posted its quarterly earnings results on Tuesday, May, 6th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.03. The biopharmaceutical company had revenue of $0.03 million for the quarter, compared to analyst estimates of $3.50 million. When did Ambit Biosciences IPO? Ambit Biosciences (AMBI) raised $114 million in an IPO on Thursday, May 16th 2013. The company issued 8,125,000 shares at a price of $13.00-$15.00 per share. What other stocks do shareholders of Ambit Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ambit Biosciences investors own include Amarin (AMRN), Bristol Myers Squibb (BMY), Cytokinetics (CYTK), Delta Air Lines (DAL) and Fortress Biotech (FBIO). Company Calendar Last Earnings5/06/2014Today8/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Sanitary services Sub-IndustryN/A Current SymbolNASDAQ:AMBI CIK1131543 Webwww.hpxcorp.com Phone+1-858-3342100FaxN/AEmployees7,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.31 Current Ratio2.07 Quick Ratio1.97 Sales & Book Value Annual Sales$518.81 million Price / Sales0.06 Cash Flow$0.08 per share Price / Cash Flow6.40 Book Value$4.90 per share Price / Book0.11Miscellaneous Outstanding Shares55,430,000Free Float26,606,000Market Cap$29.91 million OptionableNot Optionable Beta0.55 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:AMBI) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredYour Free Report (Inside)A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredThe world's #2 gold miner is running on fumes [it has to buy]Barrick, the world's second-largest gold miner, produced 7.77 million ounces in 2010. This year, output is exp...Golden Portfolio | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ambit Biosciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Ambit Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
